Key result
Andexanet alfa achieves effective hemostasis in ~79% of patients with acute factor Xa inhibitor-related bleeding.
Why the study?
Does andexanet alfa effectively and safely reverse the anticoagulant effects of direct and indirect Factor Xa inhibitors and achieve hemostasis in bleeding patients?
Does andexanet alfa effectively and safely reverse the anticoagulant effects of direct and indirect Factor Xa inhibitors and achieve hemostasis in bleeding patients?
Andexanet alfa rapidly reverses the anticoagulant activity of direct and indirect Factor Xa inhibitors and achieves effective hemostasis in nearly 80% of patients with acute life-threatening bleeding, addressing a critical unmet need in DOAC management.
Answers are grounded in this paper and cite their sources.
May aid FXa inhibitor reversal in major bleeding; leaves open confirmation of net benefit in randomized trials.
Approximately half of patients started on an oral anticoagulant in the USA now receive one of the newer direct oral anticoagulants (DOACs). Although there is an approved reversal agent for the direct thrombin inhibitor dabigatran, a specific reversal agent for the anti-factor Xa (FXa) DOACs has yet to be licensed. Unlike the strategy to reverse the only oral direct thrombin inhibitor with idarucizumab, which is a humanized monoclonal antibody fragment, a different approach is necessary to design a single agent that can reverse multiple anti-FXa medications. Andexanet alfa is a FXa decoy designed to reverse all anticoagulants that act through this part of the coagulation cascade including anti-FXa DOACs, such as apixaban, edoxaban and rivaroxaban, and indirect FXa inhibitors such as low-molecular-weight heparins. This narrative reviews the development of andexanet alfa and explores its basic science, pharmacokinetics/pharmacodynamics, animal models, and human studies.
No takes yet. Share an insight, caveat, or question.
Kaatz et al. (2017) conducted a review in Anticoagulation with Factor Xa inhibitors requiring reversal for acute major bleeding. Andexanet alfa was evaluated on Reversal of anti-Factor Xa activity and clinical hemostatic efficacy at 12 hours (reviewed across clinical trials). Andexanet alfa reduced anti-FXa activity by 89% to 94% and achieved excellent or good hemostasis in 79% of patients with acute major bleeding on FXa inhibitors in reviewed trials.
Synapse has enriched 10 related papers. Consider them for comparative context: